Neonates exposed to hepatitis B surface antigen (HBsAg)-positive mothers are at an increased risk of hepatitis B virus (HBV) infection. Depending on the mother\'s hepatitis B envelope antigen (HBeAg) status, the perinatal transmission rate in the absence of postnatal immunoprophylaxis is estimated to be 40 to 90%.[@JR140053-1] [@JR140053-2] Early HBV infection often leads to chronic hepatitis with a high rate of mortality and morbidity.[@BR140053-3] [@JR140053-4] [@JR140053-5] [@JR140053-6] Recommendations of various expert panels from international societies primarily include timely active and passive immunization with the goal of preventing vertical transmission of HBV to the child.[@JR140053-7] [@BR140053-8] [@OR140053-9]

However, there is controversy on the ideal schedule for hepatitis B postexposure prophylaxis in preterm neonates. While some studies using a three-dose strategy indicated a lower antibody response to HBV vaccination in very low-birth-weight (VLBW) infants born to HBsAg-negative mothers[@JR140053-10] [@JR140053-11] [@JR140053-12] [@JR140053-13] [@JR140053-14] other results favor a four-dose strategy.[@JR140053-15] When compared with term infants, preterm infants and especially VLBW infants exposed to HBV may be at an increased risk of acquiring HBV infection due to low immunological response to current vaccination schedules. This review will focus on the immunological response to hepatitis B immunization in preterm infants born to HBsAg-positive mothers and the influence on perinatal transmission rate. In addition, we report a case of successful hepatitis B immunization with no perinatal transmission of HBV infection in an extremely LBW infant exposed to an HBsAg-positive mother.

Case Report
===========

A male preterm infant 25^4/7^ weeks of gestational age (GA), small for GA with a birth weight of 400 g (120 g below the 3rd percentile), length of 27 cm (3rd percentile), and head circumference of 20 cm (1 cm below 3rd percentile) was born by emergency cesarean section due to an abnormal cardiotocogram. He was the child of a first time pregnant 20-year-old woman and an 18-year-old healthy father. The course of pregnancy was complicated by maternal illicit drug and chronic nicotine abuse. In addition, prenatal care revealed significant oligohydramnios and severe intrauterine growth retardation. Chromosomal analysis was normal (46, XY). A maternal serum specimen was obtained during delivery and found to be positive for HBsAg and negative for HBeAg, human immunodeficiency virus 1 and 2, and hepatitis C with results reported available about 2 hours after birth. As the HBsAg-positive status was not known in this woman before, her hepatitis B viral load was not assessed during pregnancy and no antiviral medication was in place at the time of delivery. The newborn\'s and the mother\'s liver function tests were within the normal range as determined a few days after the child\'s birth.

Because of the mother\'s HBsAg-positive status, active hepatitis B vaccine (0.5 mL, Engerix-B \[10 µg\], GlaxoSmithKline, Germany) and HB immunoglobulin (HBIG) (0.5 mL \[= 100 IU anti-HBs\], Behring CSL, Germany) were administered intramuscularly (needle length 2.3cm) into the anterolateral aspects of the left and right quadriceps muscles, respectively, 6 hours postnatally. Immunizations were well tolerated without any local or systemic reactions. On day 2, an enteral feeding protocol with breast milk was implemented.

Two subsequent doses of the same hepatitis B vaccine were administered at 1 and 2 months of age ([Fig. 1](#FI140053-1){ref-type="fig"}), again without any adverse events. At the age of 3 months, that is, 4 weeks after the third dose, a blood sample was drawn to determine HBsAg antibody (anti-HBs) and hepatitis B core antigen antibody (anti-HBc) and HBsAg. Findings revealed an adequate immunological response (anti-HBs value: 158 IU/L) and absence of HBsAg and anti-HBc suggesting that vertical transmission of HBV was highly unlikely at that point of time. A fourth dose was administered at 13 months of age, again followed by serum analyses 7 weeks later ([Fig. 1](#FI140053-1){ref-type="fig"}). Anti-HBs value was \> 1,000 IU/L without detection of HBsAg or anti-HBc antibodies.

![Postexposure active and passive hepatitis B immunization schedule.](10-1055-s-0035-1547329-i140053-1){#FI140053-1}

Material and Methods
====================

Objective
---------

To review the effect of hepatitis B immunization in preterm and LBW infants exposed to HBsAg-positive mothers.

Search Strategies
-----------------

Relevant articles published in English or German language between January 1976 and August 2014 were identified by using the PubMed bibliographic database. The search strategy included combinations of search terms (HBsAg-positive mother, preterm, LBW, immunization, postexposure prophylaxis). We included all studies or reports involving preterm infants (defined as GA \< 38 weeks), LBW (birth weight \< 2,500 g), VLBW (birth weight \< 1,500 g) and extremely LBW, (birth weight \< 1,000 g), respectively exposed to HBsAg and/or HBeAg-positive mothers who were immunized with HBIG and/or hepatitis B vaccine (independent of vaccine type or brand) within the 1st week of life. In addition, GSK and Sanofi Pasteur MSD, Germany; manufacturers of hepatitis B vaccines, were contacted for information regarding unpublished data on the outcome of neonatal hepatitis B postexposure immunization in preterm and LBW infants. Studies were excluded if the intended vaccine schedule was not completed or follow-up data (i.e., information on anti-HBs values or transmission rate of HBV) were not reported after completion of the intended vaccine schedule.

Data Extraction and Definition of Immunoprophylaxis Failure
-----------------------------------------------------------

Recorded data included vaccination schedule, birth weight, GA, vaccine dosage if mentioned, and anti-HBs values after completion of the vaccine series. Failure of immunoprophylaxis was defined as detection of HBsAg and/or anti-HBc as well as anti-HBs values \< 10 IU/L after completion of the intended vaccination schedule. Anti-HBs values between 10 and 99 IU/L were considered to be low responses.

Results
=======

The electronic search identified 85 references. Based on the defined inclusion criteria three studies were included in this review, one from the Netherlands,[@JR140053-16] one from South Korea,[@JR140053-17] and one from Taiwan[@JR140053-18] ([Fig. 2](#FI140053-2){ref-type="fig"}). In the Dutch study, results of an enhanced antenatal hepatitis B screening and neonatal immunization program from Amsterdam, comprising 691 HBsAg-positive mothers with 656 live births in the period 1993 to 1998, are reported.[@JR140053-16] Antibody response after completion of a vaccination schedule comprising active and passive immunization within 48 hours after birth, followed by vaccination at 1 and 6 months of age, was investigated in 31 infants with a birth weight of \< 2,500 g and in 49 infants with a GA of \< 38 weeks ([Tables 1](#TB140053-1){ref-type="table"} and [2](#TB140053-2){ref-type="table"}).

###### Included studies assessing the effect of active and passive hepatitis B immunization for preterm and low-birth-weight infants born to HBsAg- and/or HBeAg-positive mothers

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                      Vaccination schedule                                                              Vaccine and dosage                                                           Country
  ------------------------------------------ --------------------------------------------------------------------------------- ---------------------------------------------------------------------------- -------------------------
  Steenbergen et al (2002)[@JR140053-16]     Hepatitis B immunoglobulin within 48 h of birth\                                  No dosage for HBIG or plasma-derived vaccine reported                        Netherlands (Amsterdam)
                                             0, 1, 6 mo for plasma-derived vaccine                                                                                                                          

  Song et al (2007)[@JR140053-17]            Hepatitis B immunoglobulin within 24 h of birth\                                  Hepatitis B immunoglobulin (100 IU)\                                         South Korea
                                             0, 1, 2 months for plasma-derived vaccine[a](#FN140053-1){ref-type="table-fn"}\   Plasma-derived vaccine (10 µg) or recombinant vaccine (no dosage reported)   
                                             0, 1, 6 mo for recombinant vaccine                                                                                                                             

  Chien-Yi Chen et al (2014)[@JR140053-18]   Hepatitis B immunoglobulin within 24 h of birth\                                  Hepatitis B immunoglobulin (100 IU)\                                         Taiwan
                                             0, 1, 6 months for recombinant vaccine[b](#FN140053-2){ref-type="table-fn"}       recombinant vaccine (Engerix B 20 µg or H-B-Vax II 5 µg)                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A total of 14.6% of infants who were initially immunized with plasma-derived vaccine were switched to other types of vaccines.

Very low-birth-weight infants received first active vaccination when the infants reached body weight of 2,000 to 2,200 g followed by two subsequent doses at 1 and 6 months after the first vaccination.

###### Immunoprophylaxis failure and low anti-HBs response

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Participants with relevance to defined population (*n*)   Gestational age (wk)   Birth weight (g)   Occurrence of vertical transmission, *n* (%)   Risk for low-antibody level (anti-HBs \< 100 IU/L)\
                                                                                                                                                                                          OR (95% CI)
  ------------------------------------ --------------------------------------------------------- ---------------------- ------------------ ---------------------------------------------- -----------------------------------------------------
  Steenbergen (2002)[@JR140053-16]     31                                                        --                     \< 2,500           --                                             3.77 (1.54--9.20)

  49                                   \< 38                                                     --                     --                 2.18 (1.09--4.37)                              

  Song (2007)[@JR140053-17]            20                                                        \< 37                  --                 2 (10)                                         --

  17                                   --                                                        \< 2,500               2 (12)             --                                             

  Chien-Yi Chen (2014)[@JR140053-18]   26                                                        --                     \< 1,500           0 (0)                                          --
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; HBs, hepatitis B surface; OR, odds ratio.
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The adjusted odds ratio for low antibody response for infants with a birth weight \< 2,500 g compared with those with a birth weight of \> 2,500 g was 3.77 (95% confidence interval \[CI\], 1.54--9.20,). Low antibody values (\< 100 IU/L) were found in 9 (29%) of the 31 LBW infants. For infants \< 38 weeks of gestation the odds ratio for a weak antibody response when compared with those with a GA ≥ 38 weeks was 2.18 (95% CI, 1.09--4.37). Three infants were found to be HBsAg-positive at follow-up but no further details on birth weight or GA of these infants were reported.

In the study from South Korea,[@JR140053-17] factors associated with the failure of HBV immunoprophylaxis in 144 children (including 20 with a GA \< 37 weeks and 17 with a birth weight \< 2,500 g) born to HBsAg-seropositive mothers were evaluated. Two different vaccines with two different vaccination schedules were used ([Tables 1](#TB140053-1){ref-type="table"} and [2](#TB140053-2){ref-type="table"}): for the plasma-derived vaccine, active and passive immunization was administered within 24 hours after birth, followed by further doses of active vaccination at 1 and 2 months of age.

Immunoprophylaxis using recombinant vaccines include active and passive vaccination at birth, followed by further doses of active vaccination at 1 and 6 months of age. Specific results on antibody responses were not reported, but 2 (10%) of 20 infants \< 37 weeks of GA and 2 (12%) of 17 infants with a birth weight \< 2,500 g were reported to be immunoprophylaxis failures, that is, HBsAg was positive in serum specimens obtained 1 to 3 months after completion of the immunization series. In the study from Taiwan,[@JR140053-18] the immunogenicity of a weight-based immunization policy was retrospectively assessed in 155 preterm infants with a birth weight of \< 1,500 g. Overall, 26 of these 155 infants were born to HBsAg-positive mothers and 6 of them were also HBeAg-positive. Infants of HBsAg- and HBeAg-positive mothers received HBIG within 24 hours after birth and their first active immunization at a mean age of 57.8 days when they had reached a body weight of 2,000 to 2,200 g. Of the 20 infants born to HBsAg-positive/HBeAg-negative mothers, 12 also received HBIG immediately after birth and 8 did not. Mean age when the first dose of hepatitis B vaccine was administered in these 20 infants was 81.5 days. All 26 infants received 2 subsequent doses of hepatitis B vaccine 1 and 6 months after the first dose and none of them was positive for HBsAg or anti-HBc at follow-up.

Contact with manufacturers of hepatitis B vaccines (GSK and Sanofi Pasteur MSD) did not reveal unpublished data relevant to the topic of this review.

Discussion
==========

We present the case of an extremely LBW and growth-retarded infant born to a HBsAg-positive mother in whom we applied a four-dose active immunization schedule at 0, 1, 2, and 12 months of age in addition to administration of HBIG at birth. Protective anti-HBs serum antibody values (\> 100 IU/L) were detected after the third and fourth vaccination. To our knowledge, this is the smallest preterm infant with successful hepatitis B immunization and prevention of vertical virus transmission ever reported in the literature. This experience prompted us to perform a review on the effect of hepatitis B postexposure prophylaxis in preterm and LBW infants, including transmission rate and antibody response outcomes. Although the search strategy could not identify any study specifically evaluating the effect of hepatitis B postexposure vaccine schedules in preterm and LBW infants, the three included studies together provided data on seroprotection results in 80 LBW and preterm infants (\< 38 weeks of GA), transmission rates in 37 preterm and LBW infants (\< 2,500 g and \< 37 weeks of GA, respectively), and 26 VLBW infants.[@JR140053-16] [@JR140053-17] [@JR140053-18] LBW was significantly associated with a low antibody response (postimmunization anti-HBs value 10--100 IU/L) after active and passive hepatitis B immunization at birth and followed by two further dosages at the age of 1 and 6 months. Unfortunately, the authors of one study did not report on the hepatitis B transmission rate in these infants.[@JR140053-16] In another study,[@JR140053-17] perinatal transmission rate was assessed in 20 infants with GA \< 37 weeks and in 17 infants with birth weights \< 2,500 g of which 2 (10%) and 2 (12%), were positive for HBsAg 1 and 3 months after completion of immunoprophylaxis, respectively. These infants had received active and passive immunization immediately after birth followed by two additional doses. It is not stated whether these infants had received plasma derived (at 1 and 2 months of age) or recombinant HBsAg vaccine (at 1 and 6 months of age) and it remains unclear how many of the infants fulfilled both criteria, that is, were of LBW and born \< 38 weeks of gestation. Chen et al[@JR140053-18] reported on immunogenicity and transmission rates in 26 VLBW infants exposed to HBsAg-positive mothers. Six infants were at high risk for perinatal HBV transmission due to a positive HBeAg-carrier status of their mothers. These six infants received HBIG at birth followed by a delayed active immunization at a mean postnatal age of 57.8 days and two subsequent doses of hepatitis B vaccine 1 and 6 months after the first dose. Although no infant in this study became infected with HBV, the approach of a delayed active immunization strategy in high-risk (i.e., HBsAg/HBeAg-positive mothers) VLBW infants is unusual and not supported by any official recommendations that we are aware of.

Recommendations for HB immunization in preterm and term infants differ between countries.[@JR140053-7] [@BR140053-8] [@OR140053-9] In the United States, current immunization policy for infants with negative maternal HBsAg status suggests two different approaches of HB immunization depending on the weight of the infant: for infants with a birth weight \< 2,000 g the first HB vaccine should be administered with a delay until 1 month of age or at hospital discharge.[@JR140053-7] Data leading to the recommendation of a delayed and "noncompressed" (i.e., three doses in a 0--1--6 month interval schedule) HB immunization in infants with a birth weight \< 2,000 g is based on observations from a study published in 1992 where significantly lower conversion rates and lower postimmunization anti-HBs values were detected if HB immunization was initiated immediately after birth.[@JR140053-10] This result was confirmed by several subsequent investigations which found significantly lower anti-HBs seroconversion rates in preterm (GA between \< 34 and \< 37 weeks) infants with birth weights ranging between \< 1,500 and \< 1,800 g compared with larger and more mature infants (45--85% vs. 90--100%) when vaccinated immediately after birth followed by further doses of HBV vaccine at 1 to 2 and 6 to 7 months of age.[@JR140053-10] [@JR140053-11] [@JR140053-12] [@JR140053-13] [@JR140053-14] [@JR140053-19] However, a compressed schedule using a four-dose immunization schedule at 0, 1, 2, and 12 months of age resulted in adequate seroconversion in 95% of the infants with a birth weight \< 1,500 g born to HBsAg-negative mothers.[@JR140053-15] In infants born to HBsAg-positive mothers, immediate postnatal simultaneous administration of HBV vaccine and HBIG is an important measure to avoid vertical transmission of HBV with the consecutive risk of chronic HB.

To account for these exceptional cases and the expected lower antibody response to immediate postnatal active HB vaccination in LBW infants (defined as \< 2,000 g), the Advisory Committee on Immunization Practices (ACIP) recommends that the dose at birth should not be counted as part of the vaccination series, thereby also resulting in a compressed four-dose immunization strategy ([Table 3](#TB140053-3){ref-type="table"}).[@JR140053-7] Similar strategies to prevent perinatal transmission are recommended in the United Kingdom.[@JR140053-20] An accelerated vaccination schedule which consists of active and passive immunization at birth, followed by three further doses of HB vaccine at 1, 2, and 12 months of age, is recommended for all neonates born to HBsAg-positive mothers irrespective of GA or birth weight. This schedule was also applied in our patient. Preterm and LBW infants of two studies included in our review[@JR140053-16] [@JR140053-17] received active and passive immunization immediately after birth, followed by two further doses of HB vaccine. A delayed (weight-based) three-dose strategy was administered in the study from Taiwan,[@JR140053-18] but eight infants exposed to HBsAg-positive mothers did not receive any postexposure prophylaxis immediately after birth. Results of administration of a fourth dose (apparently scheduled at 11 months of age in the Dutch study) were not reported in any of the included studies. Although LBW was significantly associated with a low HBs-antibody response (10--99 IU/L) in the Dutch study, no further information on HB transmission in these infants was reported.[@JR140053-16] It is generally considered that anti-HBs levels ≥ 10 IU/L are sufficient to prevent HB infection.[@JR140053-21] [@JR140053-22] However, because of lack of information on the infection rate of the low antibody responders in this study, it remains unclear whether these infants were at an increased risk of acquiring HBV infection.[@JR140053-16] In the study from South Korea, the rate on perinatal HBV transmission in 20 preterm infants was 10%.[@JR140053-17] The authors concluded, that the comparatively high rate of immunoprophylaxis failure, which was independent of birth weight and GA classifications, was due to comparatively high rates of HBeAg and HBV--DNA-positive mothers (56 and 79%, respectively). It is speculative whether a four-dose schedule with the first three doses at 0, 1, and 2 months of age and a fourth dose at 12 months of age would have contributed to a lower transmission rate. In infants who received three doses of the plasma-derived vaccine, an accelerated schedule (0--1--2 months) in fact was applied and a fourth dose would not have prevented failure with this vaccine. Although no specific details were reported on birth weights or GAs, the overall vaccine failure rate for the plasma-derived vaccine when compared with the 0--1--6 month schedule of the recombinant vaccine was virtually identical (13/110 = 12 vs. 4/34 = 12%). It remains unknown, whether an accelerated four-dose schedule with the South Korean recombinant HB vaccine would have led to better results. To our surprise, the effect on perinatal HBV transmission in LBW and/or preterm infants born to HBsAg-positive mothers of different vaccination schedules with HB vaccines currently available, has not been evaluated systematically. In contrast, substantial data on immunological response of LBW infants born to HBsAg-negative mothers to HB vaccination confirm that current vaccination strategies result in high and protective antibody values.[@JR140053-7] [@BR140053-8] [@OR140053-9] [@JR140053-20]

###### Hepatitis B vaccine schedules for newborn and preterm infants (\< 2,000 g) exposed to hepatitis B surface antigen-positive mothers

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hepatitis B vaccine schedules for newborn infants born to hepatitis B surface antigen-positive mothers¶                                                                
  --------------------------------------------------------------------------------------------------------- ---------------- ------------------------------------------- --------------------
  Dose                                                                                                      Age              Dose                                        Age

  1[a](#FN140053-6){ref-type="table-fn"}                                                                    Birth (≤ 12 h)   1[a](#FN140053-6){ref-type="table-fn"}      Birth (≤ 12 h)

  HBIG[b](#FN140053-7){ref-type="table-fn"}                                                                 Birth (≤ 12 h)   HBIG[b](#FN140053-7){ref-type="table-fn"}   Birth (≤ 12 h)

  2                                                                                                         1--2 mo          2                                           2 mo

  3[c](#FN140053-8){ref-type="table-fn"}                                                                    6 mo             3                                           4 mo

                                                                                                                             4[c](#FN140053-8){ref-type="table-fn"}      6 mo (Pediarix)\
                                                                                                                                                                         or\
                                                                                                                                                                         12--15 mo (Comvax)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: Recommended vaccine schedules in the United States by Advisory Committee on Immunization Practices, 2005.[@JR140053-7]

See immunization management of preterm infants (\< 2,000 g) below:

• Hepatitis B immunization management of preterm infants weighing \< 2,000 g. HBIG + hepatitis B vaccine (≤ 12 h of birth).

• Continue vaccine series beginning at age 1--2 mo according to the recommended schedule for infants born to HBsAg-positive mothers.

• Do not count birth dose as part of the vaccine series.

• Test for HBsAg and antibody to HBsAg after completion of the vaccine series at age 9--18 mo (i.e., next well-child visit).

Recombivax HB (Merck Sharp & Dohme Corp., Kenilworth, NJ) or Engerix B (GlaxoSmithKline, Germany) should be used for birth dose. Comvax (Merck Sharp & Dohme Corp., Kenilworth, NJ) and Pediarix (GlaxoSmithKline, Research Triangle Park, NC) cannot be administered at birth or before the age of 6 wks.

Hepatitis B immunoglobulin (0.5 mL) administered intramuscularly in a separate site from vaccine.

The final dose in the vaccine series should be administered before the age of 24 wks (164 d).

As a limitation of this review the literature search was limited to the PubMed database. Therefore, we may have missed studies relevant to the topic. Furthermore, quantity of HBV in the mother\'s blood was not determined and if it was low, this might have contributed to the lack of infection of the extremely LBW infant.

Due to the small number of infants and considerable lack of information in the three studies included in this review,[@JR140053-16] [@JR140053-17] [@JR140053-18] no firm conclusions can be made on the ideal schedule of HB vaccination in LBW infants exposed to HBV. Therefore, prospective studies to determine the success of currently recommended four-dose immunization schedules in these infants should be performed. The example of our patient is encouraging in this regard.

Conclusion
==========

This case report of an extremely LBW infant born to a HBsAg-positive mother shows, that currently recommended strategies to prevent HBV infection can lead to successful immunization by prevention of vertical virus transmission even in very premature and growth-retarded infants exposed to HBsAg-positive mothers. There is very little information available from the literature on the efficacy of recommended postexposure prophylaxis for VLBW infants to prevent vertical transmission and to induce protective antibody values. We hypothesize that a four-dose schedule of HB vaccine in addition to postnatal HBIG, as recommended for preterm infants, may be effective also in VLBW infants. Future studies need to evaluate the effect of postexposure prophylaxis in a high-risk population of very premature infants.
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